OKYO Pharma Ltd. (NASDAQ:OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (“DED) and neuropathic corneal pain (“NCP”). OKYO’s flagship drug candidate OK-101 is a lipidated chemerin-peptide, designed to target a key ocular receptor controlling inflammation and ocular pain. The drug, developed by a unique proprietary membrane anchored technology, is designed to increase agonist potency and ocular residence time.


Scientific Advisory Board